Enbrel Clinical Experience
Links shared publicly online about this topic
Clinical Cases and Images: CasesBlog: Stelara (ustekinumab) and Remicade (infliximab) are effective if Enbrel (etanercept) stops working in psoriasis
casesblog.blogspot.com — “Health News Updated Daily by an Assistant Professor at University of Chicago, Internist and Allergist” View full resource at casesblog.blogspot.com
Most Recently Shared on October 29, 2010 at 2:33 am By:
Richard L.Trader,Sr Health Executive, Physician Assistant, and Therapist
Stelara (ustekinumab) and Remicade (infliximab) are effective if Enbrel (etanercept) stops working in psoriasis: A... http://bit.ly/cUPSQZ
Humira and Enbrel have best overall clinical profile for treatment of moderate to severe psoriasis: Survey
news-medical.net — “Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of moderate to severe psoriasis, the highest proportion of surveyed dermatologists and managed care organizations' (MCOs) pharmacy directors indicate that Abbott/Eisai's Humira and Amgen/Pfizer/Stiefel/Takeda's Enbrel have the best overall clinical profile when compared to other currently available agents.” View full resource at news-medical.net
Most Recently Shared on February 9, 2011 at 3:22 pm By:
Humira and Enbrel have best overall clinical profile for treatment of moderate to severe psoriasis: Survey: Deci... http://bit.ly/ieEoBf
MediGuard.org - Enbrel | Drug safety information | Monitoring more than 11,000 patients
mediguard.org — “MediGuard.org - Enbrel | Drug safety information | Monitoring more than 11,000 patients” View full resource at mediguard.org
Most Recently Shared on February 8, 2011 at 10:17 pm By:
MediGuard.org Health Organization
Approx 10% of #enbrel users experience injection site reactions: http://tinyurl.com/4ky9fnw
For the Treatment of Moderate to Severe Psoriasis, the Highest Proportion of Surveyed Dermatologists and MCOs Indicate That Humira and Enbrel Have the Best Overall Clinical Profile When Compared to Other Currently Available Agents | Business Wire
businesswire.com — “Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatme” View full resource at businesswire.com
Most Recently Shared on February 7, 2011 at 9:16 pm By:
For the Treatment of Moderate to Severe Psoriasis, the Highest Proportion of Surveyed Dermatologists and MCOs In... http://bit.ly/fgMTjb
Etanercept Overview of Clinical Experience in the Treatment of Psoriasis and Psoriatic Arthritis - QualityPoint Technologies
qualitypointtech.net — “What are the most effective biologic therapies for psoriasis and psoriatic arthritis? International Journal of Clinical Rheumatology” View full resource at qualitypointtech.net
Most Recently Shared on May 17, 2011 at 4:00 pm By:
Etanercept Overview of Clinical Experience in the Treatment of Psoriasis and Psoriatic Arthritis: What are the mos... http://bit.ly/jMaeZh
Press - News - 469 - Clinical efficacy and safety of etanercept versus sulfasalazine in ankylosing spondylitis patients
spondylitis.org — “Ankylosing spondylitis and related disease information. Ankylosing spondylitis symptoms, diagnosis, treatment, medication, educational materials, brochures. Spondylitis patient support, message boards, physician resources and more. SAA is a non-profit organization and we were the first and remain the largest resource for people affected by spondylitis in the United States.” View full resource at spondylitis.org
Most Recently Shared on January 31, 2011 at 10:48 pm By:
Spondylitis.org Health Organization
Study: Clinical efficacy & safety of etanercept (Enbrel) vs. sulfasalazine in ankylosing #spondylitis patients http://bit.ly/hon8Vc
Abbott Reports Psoriasis Phase III Results of its Investigational IL-12/23 Inhibitor Briakinumab (ABT-874) - Drugs.com MedNews
drugs.com — “Data Compares Briakinumab (ABT-874) to Etanercept, Methotrexate and Placebo in Psoriasis In four separate pivotal clinical studies presented on Friday, a greate” View full resource at drugs.com
Most Recently Shared on October 11, 2010 at 11:06 pm By:
Drugs and Devices OW OW Health
Abbott Reports Psoriasis Phase III Results of its Investigational IL-12/23 Inhibitor Briakinumab (ABT-874): D... http://bit.ly/9TMCor #drug
ACR: Single-Agent Offers Persistent Clinical Benefit in RA (CME/CE) - QualityPoint Technologies
qualitypointtech.net — “CHICAGO (MedPage Today) -- Monotherapy with etanercept (Enbrel) can keep some rheumatoid arthritis (RA) patients in long-term remission, researchers said here.” View full resource at qualitypointtech.net
Most Recently Shared on November 13, 2011 at 3:45 pm By:
ACR: Single-Agent Offers Persistent Clinical Benefit in RA (CME/CE): CHICAGO (MedPage Today) -- Monotherapy with e... http://t.co/ff0femiw
Medical News: AAD: When First Anti-TNF Fails Try a Second One - in Meeting Coverage, AAD from MedPage Today
medpagetoday.com — “MIAMI BEACH -- Half of patients with psoriasis unresponsive to high-dose etanercept (Enbrel) achieved significant improvement with ustekinumab (Stelara), investigators in a randomized clinical trial r” View full resource at medpagetoday.com
Most Recently Shared on March 21, 2010 at 4:17 pm By:
PsoriasisTx.com Dermatology and Health Site
AAD: When First Anti-TNF Fails Try a Second One - in Meeting Coverage, AAD from MedPage Today: http://bit.ly/9nQhKv via @addthis
STELARA(TM) Shows Greater Efficacy Than Etanercept For Treatment Of Moderate To Severe Plaque Psoriasis
medicalnewstoday.com — “Findings from an international, Phase 3 clinical study comparing the efficacy and safety of STELARA™ (ustekinumab) with etanercept (Enbrel®) in the treatment of moderate to severe plaque” View full resource at medicalnewstoday.com
Most Recently Shared on January 15, 2010 at 3:10 pm By:
MNT Dermatology News Dermatology and Health News
STELARA(TM) Shows Greater Efficacy Than Etanercept For Treatment Of Moderate To Severe Plaque Psoriasis http://mnt.to/3wmC
spondylitis shared http://www.medscape.com/viewarticle/721537
link.social.com — “spondylitis shared http://www.medscape.com/viewarticle/721537” View full resource at link.social.com
Most Recently Shared on May 19, 2010 at 8:42 pm By:
Spondylitis.org Health Organization
Clinical Efficacy of 3 TNF-a Inhibitors: an update re Infliximab (REMICADE), Adalimumab (HUMIRA), & Etanercept (ENBREL) http://j.mp/bge3w4
Abbott presents data from 4 briakinumab pivotal studies in psoriasis
news-medical.net — “In four separate pivotal clinical studies presented on Friday, a greater percentage of moderate to severe chronic plaque psoriasis patients treated with briakinumab, Abbott's investigational IL-12/23 inhibitor (ABT-874), achieved 75 percent or better skin clearance rates than those treated with etanercept (Enbrel®), methotrexate or placebo. Abbott presented data from all briakinumab pivotal studies in psoriasis at the European Association of Dermatology and Venereology scientific sessions.” View full resource at news-medical.net
Most Recently Shared on October 11, 2010 at 3:40 pm By:
Abbott presents data from 4 briakinumab pivotal studies in psoriasis: In four separate pivotal clinical studies pr... http://bit.ly/bUgYVP
Abbott presents data from 4 briakinumab pivotal studies in psoriasis
news-medical.net — “In four separate pivotal clinical studies presented on Friday, a greater percentage of moderate to severe chronic plaque psoriasis patients treated with briakinumab, Abbott's investigational IL-12/23 inhibitor (ABT-874), achieved 75 percent or better skin clearance rates than those treated with etanercept (Enbrel®), methotrexate or placebo. Abbott presented data from all briakinumab pivotal studies in psoriasis at the European Association of Dermatology and Venereology scientific sessions.” View full resource at news-medical.net
Most Recently Shared on October 11, 2010 at 3:39 pm By:
Stroke News: Abbott presents data from 4 briakinumab pivotal studies in psoriasis: In four separate pivotal clin... http://twurl.nl/szaew5
Rheumatology Article | Arthritis Arthritis, Juvenile Rheumatoid
mdlinx.com — “Etanercept in the treatment of disease-modifying anti-rheumatic drug (DMARD)-refractory polyarticular course juvenile idiopathic arthritis: Experience from Japanese clinical trials” View full resource at mdlinx.com
Most Recently Shared on April 15, 2011 at 9:21 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Etanercept in the treatment of disease-modifying anti-rheumatic drug (DMARD)-refractory polyarticu... http://bit.ly/ff63TA #Rheumatology
The Patient Experience | Cleveland Clinic Health
cchealth.clevelandclinic.org — “The Patient Experience | Cleveland Clinic Health” View full resource at cchealth.clevelandclinic.org
Most Recently Shared on January 5, 2011 at 4:18 am By:
Putting the care back into care-givers. http://fb.me/x3utFuqx
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Related WisdomCards
Related Health Centers
Featuring the top 3 experts for this topic
-
Richard L.Trader,Sr
Richard L. Trader, Sr. MMsc RRT PA-C FCCM Director, Institute of Health Sciences online
-
Psoriasis OW
Organizing psoriasis resources shared by health experts, advocates, and organizations into WisdomCards.
-
MediGuard.org
Live health insights from 2.5+ million users of MediGuard, the easiest way to get safety alerts and recalls for your medicines.
Advertisement
